A Single-arm, Multicenter, Open-label Phase II Clinical Study Evaluating the Efficacy and Safety of JAB-21822 Monotherapy in Patients With Locally Advanced or Metastatic Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.
Status: Recruiting
Location: See all (31) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
Patients with other advanced solid tumors (excluding NSCLC and CRC) who have progressed after prior systemic therapy or are intolerant and lack satisfactory alternative treatment options, aiming to evaluate the efficacy and safety of Glecirasib in these patients.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Patients with the KRAS p.G12C mutation confirmed through testing using prospectively validated companion diagnostic reagents or clinical trial assay (CTA) methods.
• Histologically or cytologically confirmed locally advanced unresectable or metastatic solid tumors (excluding NSCLC and CRC).
• Patients with pancreatic cancer must have progressed or been intolerant to prior gemcitabine-based chemotherapy regimens or FOLFIRINOX/mFOLFIRINOX/NALIRIFOX treatment. Patients with other types of solid tumors must have progressed or been intolerant to prior systemic therapies and lack satisfactory alternative treatment options.
Locations
Other Locations
China
Beijing Cancer Hospital
RECRUITING
Beijing
Beijing Tsinghua Changgung Hospital
RECRUITING
Beijing
Cancer Hospital Chinese Academy of Medical Sciences
RECRUITING
Beijing
Peking Union Medical College Hospital
RECRUITING
Beijing
Hunan Cancer Hospital
RECRUITING
Changsha
Hunan Provincial People's Hospital
RECRUITING
Changsha
West China Hospital of Sichuan University
RECRUITING
Chengdu
Fujian Cancer Hospital
RECRUITING
Fuzhou
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
RECRUITING
Guangzhou
Sun Yat-Sen University Cancer Center
RECRUITING
Guangzhou
The First Affiliated Hospital of Sun, Yat-sen University
RECRUITING
Guangzhou
The First Affiliated Hospital, Zhejiang University School of Medicine
NOT_YET_RECRUITING
Hangzhou
Zhejiang Cancer Hospital
RECRUITING
Hangzhou
Zhejiang Provincial People's Hospital
RECRUITING
Hangzhou
Harbin Medical University Cancer Hospital
RECRUITING
Harbin
Anhui Provincial Cancer Hospital
RECRUITING
Hefei
Shandong Cancer Hospital
RECRUITING
Jinan
The First Affiliated Hospital of Nanchang University
RECRUITING
Nanchang
Jiangsu Cancer Hospital
RECRUITING
Nanjing
Jiangsu Province Hospital
RECRUITING
Nanjing
Guangxi Medical University Cancer Hospital
RECRUITING
Nanning
The Affiliated Hospital of Qingdao University
NOT_YET_RECRUITING
Qingdao
Huashan Hospital, Fudan University
RECRUITING
Shanghai
Shanghai Changhai Hospital
RECRUITING
Shanghai
The First Hospital of China Medical University
RECRUITING
Shenyang
Tianjin Medical University Cancer Institute＆Hospital
RECRUITING
Tianjin
Hubei Cancer Hospital
RECRUITING
Wuhan
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITING
Wuhan
The First Affiliated Hospital of Xi'an Jiaotong University
RECRUITING
Xi’an
Henan Cancer Hospital
RECRUITING
Zhengzhou
The First Affiliated Hospital of Zhengzhou University